Viking Therapeutics

Company snapshot

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's clinical programs include VK2735, a novel dual agonist of the GLP-1 and GIP receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutane

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 15 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Viking Therapeutics. Not investment advice.

• approval Jun 3, 2026

  Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures

Recent activity

Latest pipeline, patent, and corporate events for Viking Therapeutics.

1. Jun 5, 2026 Clinical update

   VK2809 — Phase 2

2. Jun 5, 2026 Clinical update

   VK0214 — Phase 1

3. Jun 5, 2026 Clinical update

   Placebo — Phase 2

4. Jun 3, 2026 Partnership signal

   Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures

5. May 23, 2026 Clinical update

   VK2735 — Phase 3

View all clinical trial activity →

• What is Viking Therapeutics?

  Viking Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker VKTX. Primary therapeutic focus areas include Weight Loss, Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD), Hyperlipidemia, NASH - Nonalcoholic S

• Is Viking Therapeutics publicly traded?

  Yes. Viking Therapeutics is listed with ticker VKTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Viking Therapeutics develop or market?

  We link 3 drug profile(s) where Viking Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/viking-therapeutics#company-drugs.

• What are the latest developments for Viking Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Viking Therapeutics focus on?

  Viking Therapeutics focuses on Weight Loss, Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD), Hyperlipidemia based on our analysis of their pipeline programs and drug development activities.